矿物质皮质类受体信号传递抑制了膀癌的进展
Yujiro Nagata1,2,3, Takuro Goto1,2, Yuki Teramoto1,2
1Department of Pathology and Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA.
American journal of cancer research
|March 8, 2024
概括
矿物皮质受体 (MR) 在膀癌中起到瘤抑制作用,抑制生长和迁移. 瘤中的低MR表达与增加的死亡率相关,这表明MR激活可能是治疗目标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 矿物质皮质类受体 (MR) 在尿道癌中的作用尚不清楚.
- 研究MR的功能对于了解膀癌的进展至关重要.
研究的目的:
- 确定MR在膀癌进展中的功能作用.
- 评估MR在肌肉侵入性膀癌中的临床意义.
主要方法:
- 利用了具有MR表达的人类膀癌细胞系.
- 给药的MR配体 (阿尔多) 和对抗剂 (螺旋乳,埃普莱伦,埃萨克塞伦).
- 使用shRNA和分析的蛋白质表达 (β-catenin,c-fos,N-cadherin,E-cadherin,p53) 进行了MR敲击.
- 在肌肉侵入性膀癌的手术样本上进行免疫组织化学.
主要成果:
- 阿尔多斯特治疗减少了癌细胞的增殖和迁移;对抗剂逆转了这些效应.
- 消灭MR会增加细胞活力,迁移和殖民地形成.
- 导致MR敲击导致卡德林切换和关键蛋白质的改变表达.
- 在瘤中观察到较低的MR表达与正常泌尿道相比.
- 瘤中的高MR表达与显著降低癌症特异性死亡率和改善生存率相关.
结论:
- 核磁共振信号作为瘤抑制剂在尿癌.
- 强烈的MR表达是肌肉侵入性膀癌中更好的生存率的独立预测指标.
- 同时使用抗矿物质皮质类药物可能会促进膀癌的进展.
相关概念视频
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Endocrine Signaling
64.3K
Endocrine cells produce hormones to communicate with remote target cells found in other organs. The hormone reaches these distant areas using the circulatory system. This exposes the whole organism to the hormone but only those cells expressing hormone receptors or target cells are affected. Thus, endocrine signaling induces slow responses from its target cells but these effects also last longer.
64.3K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
730
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
730
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Canonical Wnt Signaling Pathway
8.7K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429


